Literature DB >> 27547965

What is the evidence base for atopic eczema treatments? A summary of published randomized controlled trials.

H Nankervis1, K S Thomas1, F M Delamere1, S Barbarot1, S Smith1, N K Rogers1, H C Williams1.   

Abstract

Atopic eczema (AE) is a common chronic inflammatory skin condition. While many AE treatment options are available, the evidence to support their efficacy varies in depth and quality. In 2000, a National Institute for Health Research (NIHR) Health Technology Assessment systematic review identified and evaluated existing randomized controlled trials (RCTs) of AE treatments. To ensure continuing utility, the NIHR commissioned an update to the review. Here, we present an overview of the updated report and its key findings. Systematic reviews and RCTs of AE treatments that included participants with AE (criteria based or diagnosed) were identified using Medline, Embase, CENTRAL, Latin American and Caribbean Health Sciences, Allied and Complementary Medicine Database, Cumulative Index to Nursing and Allied Health Literature and Cochrane Skin Group Specialised Register [searched to 31 August 2013 (RCTs) and 31 December 2015 (systematic reviews)]. Outcome measures included symptoms, AE severity, quality of life and adverse effects. Study quality was assessed using the Cochrane Collaboration risk of bias tool. Of the 287 new RCTs identified, only 22 (8%) were judged to have a low risk of bias. When combined with RCTs from the previous review (n = 254), we found 'reasonable evidence of benefit' for corticosteroids, calcineurin inhibitors, Atopiclair® , ciclosporin, azathioprine, ultraviolet radiation and education programmes. Interventions with reasonable evidence of 'no benefit' included some dietary interventions, ion exchange water softeners, multiple daily applications of topical corticosteroids and antibiotic-containing corticosteroids for noninfected AE. Many common treatments lack evidence of efficacy and warrant further evaluation. The evidence base for AE is still hampered by poor trial design and reporting. The trials included in this review were used to establish the Global Resource of EczemA Trials (GREAT) database.
© 2016 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27547965     DOI: 10.1111/bjd.14999

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

Review 1.  A Systematic Scoping Literature Review of Publications Supporting Treatment Guidelines for Pediatric Atopic Dermatitis in Contrast to Clinical Practice Patterns.

Authors:  Elaine C Siegfried; Jennifer C Jaworski; Paola Mina-Osorio
Journal:  Dermatol Ther (Heidelb)       Date:  2018-06-01

2.  Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness.

Authors:  Miriam Santer; Matthew J Ridd; Nick A Francis; Beth Stuart; Kate Rumsby; Maria Chorozoglou; Taeko Becque; Amanda Roberts; Lyn Liddiard; Claire Nollett; Julie Hooper; Martina Prude; Wendy Wood; Kim S Thomas; Emma Thomas-Jones; Hywel C Williams; Paul Little
Journal:  BMJ       Date:  2018-05-03

Review 3.  Systematic review of self-management interventions for people with eczema.

Authors:  M J Ridd; A J L King; E Le Roux; A Waldecker; A L Huntley
Journal:  Br J Dermatol       Date:  2017-08-02       Impact factor: 9.302

4.  The widespread use of topical antimicrobials enriches for resistance in Staphylococcus aureus isolated from patients with atopic dermatitis.

Authors:  C P Harkins; M A McAleer; D Bennett; M McHugh; O M Fleury; K A Pettigrew; K Oravcová; J Parkhill; C M Proby; R S Dawe; J A Geoghegan; A D Irvine; M T G Holden
Journal:  Br J Dermatol       Date:  2018-07-24       Impact factor: 9.302

5.  Emollient prescribing formularies in England and Wales: a cross-sectional study.

Authors:  Jonathan P Chan; Grace Boyd; Patrick A Quinn; Matthew J Ridd
Journal:  BMJ Open       Date:  2018-06-12       Impact factor: 2.692

6.  Efficacy, Safety, and Immunomodulatory Effect of the Intramuscular Administration of Autologous Total Immunoglobulin G for Atopic Dermatitis: A Randomized Clinical Trial.

Authors:  Dong Ho Nahm; Young Min Ye; Yoo Seob Shin; Hae Sim Park; Myoung Eun Kim; Byul Kwon; Su Mi Cho; Jinjoo Han
Journal:  Allergy Asthma Immunol Res       Date:  2020-11       Impact factor: 5.764

7.  The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate-to-severe atopic eczema.

Authors:  F M Vermeulen; L A A Gerbens; J Schmitt; M Deleuran; A D Irvine; K Logan; W Ouwerkerk; C Vestergaard; C Flohr; P I Spuls
Journal:  Br J Dermatol       Date:  2020-03-18       Impact factor: 9.302

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.